Aphton gets lift from positive trial results

MichaelBaron

Aphton
apht
is rising more than 17 percent to $3.60 after the Miami firm reported favorable results of a phase II trial of the use of its G17DT drug and chemotherapy to treat patients with metastatic stomach cancer. The company reported an overall tumor response rate of 51 percent for the trial, and said that 82 percent of the patients either experienced tumor shrinkage or stable disease.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.